NASDAQ$FRMM
Forum Markets Inc · Q1 2025 earnings
Q1 2025 earnings ·
Briefing
180 Life Sciences reported Q1 2025, net loss of $2.4M, diluted EPS of $-0.67.
For Q1 2025, 180 Life Sciences reported a net loss of $2.4M, diluted EPS was $-0.67. Management discusses operating trends, capital, and sector risks in the quarterly filing.
- Net loss $2.4M.
- Diluted EPS $-0.67.
- 180 Life Sciences highlights liquidity, execution, and sector-specific risks in MD&A.
Headline financials
Revenue & EPS history
ETHZilla Corp · Revenue · Quarterly
$6.39K
Revenue by segment
ETHZilla Corp · $2.86M total across 2 segments · Q1 2026
- Staking$1.77M—61.9%
- Aircraft Engine Rental$1.09M—38.1%
Forward guidance
Clinical-stage biotech filers emphasize trial milestones, regulatory paths, and cash runway; product revenue is limited or absent.
Tailwinds
- Pipeline progress and partnership optionality.
- Cash balances funding operations into upcoming catalysts.
- Regulatory designations where applicable.
Headwinds
- Trial failure or regulatory delay risk.
- Dilution from equity raises.
- No near-term product revenue for most programs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 9 quarterly earnings reports · overlaid with Q1 2025
-3.0%
Avg return
Earnings day
-6.6%
Avg return
5 days after
-9.3%
Avg return
30 days after
40%
4 / 10 earnings
Positive
+5.9%
Q4 2020
Best reaction
-23.7%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -23.7% | -14.4% | +10.1% | |
| Q3 2025 | -8.2% | -29.7% | -51.1% | |
| Q2 2025 | +3.6% | +31.7% | +49.3% | |
| Q1 2025 | +5.4% | +3.6% | -11.3% | |
| Q3 2024 | -7.3% | -18.7% | -33.2% | |
| Q2 2024 | -3.4% | +2.3% | +0.1% | |
| Q1 2024 | -3.0% | -23.5% | -22.5% | |
| Q4 2021 | -0.8% | -7.3% | -18.8% | |
| Q3 2021 | +1.5% | -11.0% | -0.7% | |
| Q4 2020 | +5.9% | +0.5% | -14.5% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro